Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER IMMUNOTHERAPY

Prevention of CAR-T-cell dysfunction

The overexpression of the transcription factor c-Jun improves chimeric-antigen-receptor T-cell functionality and enhances the killing of low-antigen-expressing liquid and solid cancers in mice.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: c-Jun overexpression prevents T-cell dysfunction.

References

  1. 1.

    Long, A. H. et al. Nat. Med. 21, 581–590 (2015).

    CAS  Article  Google Scholar 

  2. 2.

    Fraietta, J. A. et al. Nat. Med. 24, 563–571 (2018).

    CAS  Article  Google Scholar 

  3. 3.

    Lynn, R. C. et al. Nature https://doi.org/10.1038/s41586-019-1805-z (2019).

    CAS  Article  Google Scholar 

  4. 4.

    Man, K. et al. Immunity 47, 1129–1141 (2017).

    CAS  Article  Google Scholar 

  5. 5.

    Quigley, M. et al. Nat. Med. 16, 1147–1151 (2010).

    CAS  Article  Google Scholar 

  6. 6.

    Pauken, K. E. et al. Science 354, 1160–1165 (2016).

    CAS  Article  Google Scholar 

  7. 7.

    Sen, D. R. et al. Science 354, 1165–1169 (2016).

    CAS  Article  Google Scholar 

  8. 8.

    Paley, M. A. et al. Science 338, 1220–1225 (2012).

    CAS  Article  Google Scholar 

  9. 9.

    Miller, B. C. et al. Nat. Immunol. 20, 326–336 (2019).

    CAS  Article  Google Scholar 

  10. 10.

    Martinez, G. J. et al. Immunity 42, 265–278 (2015).

    CAS  Article  Google Scholar 

  11. 11.

    Liu, X. et al. Nature 567, 525–529 (2019).

    CAS  Article  Google Scholar 

  12. 12.

    Khan, O. et al. Nature 571, 211–218 (2019).

    CAS  Article  Google Scholar 

  13. 13.

    Porter, D. L. et al. Sci. Transl. Med. 7, 303ra139 (2015).

    Article  Google Scholar 

  14. 14.

    Walker, A. J. et al. Mol. Ther. 25, 2189–2201 (2017).

    CAS  Article  Google Scholar 

  15. 15.

    Sadelain, M., Rivière, I. & Riddell, S. Nature 545, 423–431 (2017).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Arlene H. Sharpe.

Ethics declarations

Competing interests

A.H.S. has patents on the PD-L1/PD-L2/PD-1 pathway and on tumour immunotherapy licensed by Roche, Genentech and Novartis (US patent nos. 7,432,059, 7,722,868, 8,652,465, 9,457,080, 9,683,048, 9,815,898, 9,845,356, 9,988,452, 10,202,454 and 10,370,446), consults for Novartis, serves on the scientific advisory boards for Surface Oncology, SQZ Biotech, Elstar Therapeutics, Elpiscience, Selecta and Monopteros, and has received research funding from Merck, Novartis, Roche, Ipsen, UCB and Quark Ventures. The remaining authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

LaFleur, M.W., Miller, B.C. & Sharpe, A.H. Prevention of CAR-T-cell dysfunction. Nat Biomed Eng 4, 16–17 (2020). https://doi.org/10.1038/s41551-019-0512-2

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing